Latham & Watkins Advises Ro in Acquisition of Kit

A corporate deal team advises the company in its transaction to expand at-home diagnostics and preventative care capabilities.

July 01, 2021

Ro, the healthcare technology company, has announced the acquisition of at-home diagnostics company Kit. The acquisition expands the diagnostics capabilities and lab infrastructure of Ro's vertically-integrated primary care platform and builds on the company's existing strengths, including nationwide telehealth, pharmacy, lab processing, and in-home testing and care services. Kit's at-home, self-administered testing solutions will enable Ro to facilitate patient-centric primary care experiences for an expanded scope of conditions and support chronic and preventive care, virtually and in patients' homes.

Latham & Watkins LLP represents Ro in the transaction with a corporate deal team led by New York partner Peyton Worley and Los Angeles partner Brian Duff, with Los Angeles associate Todd Noelle and New York associate Eduard Grigoryan.

The firm also previously advised Ro in its acquisition of Modern Fertility, its Series D Financing, and its acquisition of Workpath.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.